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Abstract
The purpose of this paper is to present a 
Quality Management System (QMS) for computer 
systems validation and to identify and demonstra-
te the validation process on a practical case of a 
pharmaceutical company. Based on the European 
and the US legal requirements, we define QMS for 
computer system validation elements. Validation 
process example based on the use of a general 
V-model provides a thorough understanding of 
the actual validation implementation in practice. 
Computer system validation in a concrete organi-
zation can be implemented, based on general and 
specific standard operating procedures which form 
the QMS. Planning, Specifying, Development/
Building, Verification and Report validation 
activities are presented through process dia-
grams based on a practical Supervisory Control 
and Data Acquisition (SCADA) manufacturing 
computer-aided system validation example. 
Empirical part employed two research strategies: 
a single case study and action research. Presented 
computer system validation QMS and process 
can provide a guideline for all companies where 
computer systems are important. Although the pre-
sented QMS and process for the computer system 
validation are related to a specific pharmaceuti-
cal company case and its legal requirements, the 
experience from this highly regulated industry can 
be appropriately used in other less regulated indu-
stries. For verification of the proposed model, they 
need to be further tested within the pharmaceutical 
and other less regulated industries. 
Keywords: Quality Management System, 
computer systems, validation, V-model, pharma-
ceutical industry
1. INTRODUCTION
In today’s world, when we operate with
electronic records, the possibility of chang-
ing or copying the contents of electronic 
records, without leaving any visible trace 
of the change, is extremely high. According 
to the European Compliance Academy 
(2011a, p. 8), even in the case of the use 
of computer systems, regulatory authori-
ties want to ensure data integrity through 
reliable systems that detect and display er-
rors. To ensure the integrity of the data, the 
regulatory authorities require the computer 
systems validation in accordance with their 
requirements. The world’s leading regulato-
ry bodies that set minimum conditions and 
limitations, both in general and in the field 
of computer-aided systems in the pharma-
ceutical industry, are the US Food and Drug 
Administration (FDA) and the European 
Medicines Agency (EMA) (European 
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Commission, 2013a, 2013b; US FDA, 
2013a, 2013b). Pharmaceutical companies 
are expected to establish a quality system 
at all levels of the organization and assure 
traceability of production and supportive 
processes (MetricStream, 2014). The pa-
per deals with the computer system quality 
assurance in the pharmaceutical industry, 
where data integrity is crucial (Sai et al., 
2019; Ranbaxy Laboratories Limited, 2014, 
pp. 1-20), since today there is virtually no 
production process that is not regulated and 
controlled by a single, or multiple computer 
systems.
The regulation of computer system 
validations is, on the one hand, very gen-
eral, but on the other, it states quite clear-
ly what is required from an organization. 
According to Velkovrh Remec (2007), both 
the US and the EU legislations require the 
validation of all critical procedures, pro-
cesses and systems and the education of 
all individuals, involved in the process. 
Regulatory bodies also give numerous rec-
ommendations for the implementation of 
specific systems validation. In the field of 
computer system validation in the pharma-
ceutical industry, the well-known profes-
sional manual of the International Society 
for Pharmaceutical Engineering Good 
Automated Manufacturing Practice- ISPE 
GAMP5 (2008) has been developed. ISPE 
GAMP5 interprets regulatory requirements 
for the computer systems validation and 
aids in setting up a quality system for vali-
dating computer systems.
In terms of quality of computer systems 
in the pharmaceutical industry, we distin-
guish between three concepts. The first is 
to create a quality model, where we move 
from legal requirements to the first drafts 
and frameworks, defining what we need to 
provide in the field of computer systems 
in the pharmaceutical industry. From these 
drafts, we define standard operating proce-
dures, which interpret regulatory require-
ments in more detail, and form the elements 
of the Quality Management System (QMS) 
for computer system validation. The third 
step is execution of validation activities on 
an actual computer system, by using the es-
tablished QMS. 
Based on legal requirements of the phar-
maceutical industry, Sallubier and Rusjan 
(2017) developed a general model of QMS 
for computer systems validation and con-
cluded that we can distinguish between gen-
eral and specific standard operating proce-
dures. They emphasised the need of testing 
the appropriateness of the presented general 
model by using it within the pharmaceutical 
industry. 
The purpose of this paper is to present a 
QMS for computer systems validation and 
to identify and demonstrate the validation 
process on a practical case of a pharmaceu-
tical company. QMS is established, based 
on the European and the US regulatory re-
quirements, which are basic and general, 
and, therefore, cannot be directly applied 
within a company. Instead, every regulatory 
requirement needs interpretation and for-
malization in the company procedures, and 
we must assure that following activities are 
performed, according to these interpreta-
tions and procedures. 
The paper addresses two basic research 
questions: 
1. What are the standard operating proce-
dures forming a specific pharmaceuti-
cal company QMS for computer sys-
tem validation; 
2. How to perform the validation of the 
computer system, considering the 
pharmaceutical industry regulatory 
requirements. 
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To answer these questions, the paper 
first outlines the legal requirements gov-
erning the pharmaceutical industry and by 
comparing them defines the basic QMS ele-
ments for computer system validation. This 
is followed by an example of the process of 
validating a computer-supported produc-
tion system in the pharmaceutical industry, 
which provides a thorough understanding 
of the actual validation implementation in 
practice and its connections with regulatory 
requirements. As a basic starting point for 
identifying the process of validating a com-
puter system, we used the V-model method-
ology approach to validation, which is the 
most widespread within the area of comput-
er-based system  validation in the pharma-
ceutical industry.
2. METHODS
The paper identifies the European and 
the US legal requirements governing the 
pharmaceutical industry by using descrip-
tive and comparison methods. Then, we 
design a QMS for computer systems valida-
tion, by using classification and compilation 
methods.
The usefulness of the designed QMS 
was tested on a specific case within phar-
maceutical company. In this empirical 
part, we, therefore, employed two research 
strategies; a single case study and action 
research. We intended to analyse whether 
the general and specific standard operating 
procedures, which form the QMS, provide 
an appropriate framework for the validation 
of a concrete project of Supervisory control 
and data acquisition (SCADA) manufac-
turing computer system implementation. 
The validation example was based on the 
use of a general V-model for validation of 
computer systems. A single case study may 
be justifiable, when the research topic is in 
its early stages (Eisenhardt, 1989), when it 
is used to persuade (Siggelkow, 2007), and 
when used as a representative/typical, or 
a revelatory case (Yin, 2009). Action re-
search is a practice-oriented intervention-
ist research method that aims to address a 
phenomenon in its practical context, i.e. 
to solve a practical problem through col-
laboration between researchers and prac-
titioners. It is focused on the improvement 
of both practice and body of knowledge 
through intervention (Gill, Chew, 2019). 
Being a participatory approach, it is ide-
ally suited to monitoring change process 
and outcomes (Koshy et al., 2011). Testing 
practical computer system validation 
against conceptual frameworks follows the 
suggestion that action research should have 
implications beyond the immediate project 
and that results could inform other contexts 
(Saunders et al., 2009), in our case other 
less regulated industries.
3. REGULATORY 
REQUIREMENTS IN THE 
PHARMACEUTICAL 
INDUSTRY
When considering current European 
regulatory requirements, we rely on the 
EU Legislation rules for governing medici-
nal products in the European Union, called 
EudraLex. EudraLex guidelines consist of 
10 volumes and computer systems are de-
scribed in Volume 4, which regulates good 
manufacturing practice (GMP). Although 
Volume 4 includes several chapters and an-
nexes, only two of them are directly related 
to the validation of the computer systems: 
Chapter 4, which describes good docu-
mentation practices and Annex 11, which 
describes computer systems (European 
Commission, 2013a). Qualification and 
validation in general are described in Annex 
15.
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As stated in EudraLex, Volume 4, 
Chapter 4 (European Commission, 2011a, 
p. 2), document management is a key part 
of quality assurance and of operating in ac-
cordance with good manufacturing prac-
tice. Annex 11 relates to all types of com-
puter systems, which are classified as 
GxP. GxP refers to systems used in good 
practices, where »x« represents a variable. 
So GxP can for example be GMP (Good 
Manufacturing Practices) or GLP (Good 
Laboratory Practices) etc. IT applications 
and IT infrastructure, which are subject to 
qualification activities, are also included 
into these guidelines. Regulation empha-
sise that using computer systems instead 
of manual operations shall not have nega-
tive impact on the product quality, process 
control or quality assurance and should not 
increase the process overall risks (European 
Commission, 2011b, p. 2).
According to the European Compliance 
Academy (2011a, pg. 11) the follow-
ing are the key points from Annex 11 that 
should be considered in computer system 
validation:
• Described principles apply for GxP and 
not only for GMP.
• Risk based approach should be consid-
ered in all areas.
• Electronic records are acceptable.
• During validation, the focus is on 
checking system design,
• External suppliers of GxP relevant IT 
systems are taken into consideration,
• Milestone between the validation phase 
and the operational phase of IT systems 
should be clear
US regulatory agency FDA and its regu-
latory requirements can be found in the sec-
tion Code of Federal Regulations (CFR). 
For validation of computer systems, 21 
CFR Part 211 and 21 CFR Part 11 are im-
portant. Number 21 represents the section 
of foods and medicines, Part 211 repre-
sents current good manufacturing practices 
(cGMP), and Part 11 represents electronic 
records and electronic signatures (U.S. 
Food and Drug Administration - FDA, 
2013a, 2013b).
Crucial for the computer system vali-
dation from FDA point of view is 21 CFR 
Part 11, which covers electronic records 
and electronic signatures and includes (U.S. 
Food and Drug Administration - FDA, 
2013b):
• System controls (closed and open type 
of computer system) – system valida-
tion, electronic records security, unau-
thorized access controls, system change 
management etc.,
• Controls for electronic signatures – 
signee identification, timestamp, re-
sponsibility (e.g. author, reviewer, 
approver),
• Connection between electronic signa-
ture and electronic data,
• Users identification – biometrical iden-
tification, username and password, user 
administration etc. 
Lopez (2012) states that 21 CFR Part 
11 requirements are considering more 
technical and procedural controls in case 
of electronic records (creation, modifica-
tion, storage, archiving, copy, restoration) 
and electronic signatures. Annex 11, on the 
other hand, covers all activities, needed for 
computer system validation. To be able to 
validate computer systems, we, therefore, 
also need to consider a broader picture, 
which includes the regulatory requirements 
21 CFR Part 211 (for computer systems 
subsections D (§211.68) and E (§211.80). 
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4. ESTABLISHING QUALITY 
SYSTEM FOR COMPUTER 
SYSTEM VALIDATION 
To develop a quality system for the 
computer systems validation, the le-
gal requirements must be respected and 
fully implemented in the quality system. 
Establishing a successful quality system 
requires creating instructions and policies 
(which represent standard operating pro-
cedures - SOP), that summarize the parts 
of the legal requirements, which are then 
followed by all employees in the organiza-
tion. We can distinguish between general 
and specific standard operating procedures 
(Sallubier and Rusjan, 2017). 
The general SOP, developed in case of a 
pharmaceutical company, which are intend-
ed for use within most of the activities and 
business processes of the organization, are 
as follows: 
• Procedures for good documentation 
practice;
• Procedures, which determine ap-
proaches and time periods of archiv-
ing for different records types in both, 
electronic and paper form. This is im-
portant for record accessibility and is 
needed, e.g. in cases of product recalls 
from the market, if investigations of 
deviations from good manufacturing 
practices need to be conducted, or in 
other cases when records are evidence 
of proper implementation of processes 
(e.g. manufacturing, laboratory);
• Procedures which prescribe trainings 
for users, e.g. frequency and type of 
trainings. From the computer system 
point of view, this is very important, 
because when a system’s functional-
ity is developed or upgraded, conse-
quentially, the work instructions or 
user manuals are changed accordingly. 
From the point of view of regulatory 
requirements, this means that all com-
puter system users should be adequate-
ly trained, based on the latest valid 
work instructions or user manuals;
• Procedures, which prescribe inter-
nal audits implementation in the 
organization;
• Procedures, which prescribe supplier 
audits, in regard to their quality system 
appropriateness and their regulatory re-
quirements knowledge;
• Procedures, which monitor deviations 
from good practices management. 
These procedures can also include 
guidelines for conducting investigation 
of deviations;
• Procedures, which prescribe suppliers 
and suppliers’ contracts management.
In addition to the general SOP, which 
support multiple business processes in an 
organization, we also need specific SOP 
for the implementation of computer system 
validation. These are procedures that are re-
lated to the specifics of validation, and the 
most important ones in the case of a phar-
maceutical company are:
• The overall general procedure that 
prescribes the computer systems 
validation; 
• Execution of High-Level Risk 
Assessment; 
• Assessment of computer system 
supplier; 
• Management of changes in computer 
systems;
• Computer system access control and 
authorization management; 
Journal of Contemporary Management Issues
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• Performing backups, archiving elec-
tronic records, and restoring a comput-
er system;
• Computer system operational continu-
ity assurance;
• Computer system Configuration
management;
• Computer system Incident 
management;
• Computer system inventory;
• Computer system periodic reviews;
To assure appropriate use of the SOP 
social aspect is of critical importance. Sing 
et al. (2018) identify and explain common 
problems related to social issues challenges 
in organization and governance, execution, 
training, and personnel. 
5. COMPUTER SYSTEM LIFE
CYCLE WITH VALIDATION
CASE EXAMPLE
5.1. Computer system life cycle
To ensure regulatory compliance, as 
well as that the computer system operates 
within the required specifications, we must 
consider the computer system life cycle 
(PIC/S, 2007, p. 7), which provides an un-
derstanding of the requirements that have 
to be met, regarding the computer system 
and systematic development activities, im-
plementation, application and computer 
system retirement. Figure 1 shows the com-
puter system life cycle concept as a whole, 
composed of four phases, as indicated in 
the GAMP5 (International Society for 
Pharmaceutical Engineering - ISPE, 2008, 
p. 26) and the five fundamental activities 
for the computer system project phase/vali-
dation - planning, specifying, building/de-
velopment, verification and report.
The project phase is subject to the com-
plete computer system validation, where we 
follow the V-model. In the computer system 
validation and IT applications, the V-model 
is primarily used for the purpose of mini-
mizing the quality risks of the computer-
aided system, or IT applications and for 
improving quality (International Society for 
Pharmaceutical Engineering - ISPE, 2008).
Once the project phase is completed, 
the computer system enters the operat-
ing phase, which means the computer sys-
tem production use. Once the system is in 
regular use, users can request the system 
upgrade and add new functionalities to the 
computer system, but there may also be a 
process change, or some other change to 
the computer system that needs to be im-
plemented. In the case of changes that do 
not significantly affect the computer system 
operation, we do not need to revalidate the 
entire computer system, but only the part of 
the system that has changed. Therefore, the 
validation scope is smaller.
Figure 1. Computer system life-cycle model
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Over time, when a computer system can 
no longer be used to the full extent, or is re-
moved from operational use for any other 
reason, we move into the retirement phase, 
where such a system needs to retire, accord-
ing to the prescribed general procedures. 
Upon computer system retirement, the great-
est attention should be given to the retention 
of GxP relevant electronic records (data) on 
a computer system, so that they remain ac-
cessible to authorized persons and fully read-
able for a number of years (usually 10 years) 
after the computer system retirement. In case 
when the retired computer system is replaced 
by a new computer system, we can perform 
data migration into a new system, thus en-
suring the data availability. The project phase 
will be explained in more detail, since it is of 
key importance, if we want to successfully 
validate the computer system.
5.2. Validation process example 
Computer-based systems validation 
is logically defined as a project (project 
phase), as illustrated in Figure 1, since the 
computer system validation ends, when the 
system enters the production phase (opera-
tional use). To facilitate illustration of the 
computer-based system validation through a 
concrete case, we provide key information 
about the selected computer system. 
A technologist in the production of a 
pharmaceutical company wants to replace 
a manually driven process with the auto-
matic one, to be able to improve production 
process control and management. This indi-
vidual must continuously review and adjust 
critical process parameters, such as tempera-
ture, speed, and time of mixing in the pro-
duction process so that parameters do not 
exceed specified limits. Their activities also 
include sequencing of production steps, in 
accordance with the instructions of the batch 
record. In this case, the technologist is a 
user, who begins writing User Requirements 
Specifications (URS) for a computer system. 
In our case, this system is SCADA, which 
enables monitoring and controlling the pro-
duction process. Therefore, the technolo-
gist in our case needs functionality of the 
SCADA system, displaying on the screen the 
necessary information and enabling them to 
check the historical process data, e.g. graphi-
cally (x axis: time, y axis: critical parameters 
value, e.g. temperature, mixing speed, mix-
ing time....). Important functionality needed 
also include the temperature and the mix-
ing speed regulation. Additionally, it would 
make sense to have recipes stored on the 
SCADA system, and consequently provide 
automatic step sequencing and execution 
of the functions of tempering, mixing, etc. 
Another user requirement is that production 
can run in two modes; manual and automatic 
mode, where technologist only checks the 
SCADA system occasionally and intervenes 
only, when corrections are necessary.
Examination of regulatory requirements 
and professional literature (US FDA, 2002, 
pp. 1-34; US FDA, 2003, pp. 1-9; US FDA, 
2004, pp. 7-8; US FDA, 2006, pp. 3-24; US 
FDA, 2013a; US FDA, 2013b; European 
Commission, 2011a, pp. 2-5; European 
Commission, 2011b, pp. 2-9; European 
Compliance Academy, 2011a, pp. 2-12; 
European Compliance Academy, 2011b, 
pp. 3-46; European Compliance Academy, 
2011c, pp. 3-31; International Society for 
Pharmaceutical Engineering - ISPE, 2008, pp. 
65-79; PIC/S, 2007, pp. 1-50; Huber, 2012) 
leads us to the computer system validation 
process model, described in the next section. 
Through the process diagrams, we pre-
sent an example of the SCADA computer 
production system validation process, 
composed of planning, specification, build-
ing/development, verification, and report 
sub-processes. 
Journal of Contemporary Management Issues
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5.3. Computer system project phase/
validation process 
5.3.1. Planning sub-process 
Planning sub-process diagram (Figure 
2) shows first activities that should be im-
plemented in case when a new computer 
system is introduced. 
Figure 2. Sub-process diagram - Planning
A more detailed description of the spe-
cific steps within the planning sub-process 
is presented below.
[K1] New system requirement
The user in the production is thinking 
about a new computer-based system that 
would give them useful information, re-
garding the production process and enable 
9
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the management and control of the produc-
tion process. Specifically, the user is consid-
ering the SCADA system.
[K2] Create User Requirement 
Specification (URS)
The user writes down his ideas of the 
computer system, in our case - the SCADA 
system. Each requirement has its own 
unique identifier (e.g. URS-01 etc.), in or-
der to assure traceability of the require-
ments in the next steps of validation and to 
help preventing omitting any of the desired 
system functionalities in the process of the 
computer system development. Unique 
identification facilitates control of whether 
all system functionalities were tested.  
The technician, who is a SCADA sys-
tem user and an expert in the production 
process management field, usually does 
not have sufficient knowledge of computer 
systems regulations, and therefore the qual-
ity assurance (QA) manager, an expert in 
the field of computer systems (eCompli-
ance), gets involved in the process. In our 
case, the QA manager adds additional sys-
tem requirements for data integrity man-
agement (e.g. data deletition prevention, 
user data access restrictions, system access 
levels etc.), requirements for alarm moni-
toring, and versioning of recipes stored in 
the computer supported system. An indi-
vidual at this position also adds require-
ment for enabling events history, which 
can show us who worked on the SCADA 
system, what they were doing, when and, 
under certain conditions, why they took a 
certain step. Additionally, the same person 
establishes the rules for controlling access 
to the SCADA system, periodic scans of the 
SCADA system, managing deviations from 
good manufacturing practice, managing 
changes on a computer system, etc. Other 
participants, contributing to identifying 
the requirements, are those responsible for 
health, safety, and environment (HSE) and 
information security officers. The result is 
creation of an URS [R1] document. 
Table 1 provides an example of an URS 
document with three very simple require-
ments for the computer-based system func-
tionality: in the first column, we define a 
unique request identifier (ID) for the pur-
pose of ensuring traceability; in the second 
column, we specify the request for a com-
puter-supported system, and the third col-
umn specifies the requirement criticality, in 
terms of the level of importance related to 
this requirement. For example, we can say 
that the requirement is Essential, Important, 
or Desired.
Table 1. Example of URS – Functionalities in the URS document
URS ID Requirement Criticality
URS-x-01 … Essential/Important/Desired
… … …
URS-F-49 Screen display of control system must show the entire production process on one screen with process values. Essential
URS-F-50 The control system must show on the screen display, who is signed in, and the date and time. Essential
URS-F-51
The control system must record all process parameters in the 
graph with the time on the x-axis and parameter values on 
the y-axis and enable a real-time display of these parameters.
Essential
… … …
URS-x-n User requirement – n Essential/Important/Desired
Journal of Contemporary Management Issues
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[K3] Create High Level Risk 
Assessment (HLRA)
With HLRA, we perform the original 
computer-based system classification - GxP 
relevance of the computer-based system 
and the computer system/application cate-
gorization. With the purpose to ensure easi-
er approach to validation, computer systems 
are classified into one of the GAMP catego-
ries that represent a standard for computer 
systems in the pharmaceutical industry 
(International Society for Pharmaceutical 
Engineering - ISPE, 2008, pp. 128-132; 
Tedstone, 2012; McDowall, 2010, pp. 22-
31). As far as the SCADA system catego-
rization, we determined it belongs to the 
GAMP4 category (for controlling and man-
aging production), being a configurable 
computer system. In our case, platform (e.g. 
Proficy iFix) on the SCADA system will be 
modified and configured by an integrator 
(supplier), according to our business needs 
and the URS. 
In HLRA, we also determine if the com-
puter system is 21 CFR Part 11 relevant or 
not (we ask ourselves whether the system 
will store electronic records or use elec-
tronic signatures). In our case, the com-
puter system will store process data that 
are classified as GxP relevant, therefore the 
system falls under 21 CFR Part 11 regula-
tory requirements. Electronic signatures 
will not be used. In addition, in HLRA, we 
determine information security (ISEC) im-
pact, health, safety and environment (HSE) 
impact and impact on personal data. On the 
basis of the HLRA [R2] result, we decide 
which computer system validation activities 
are needed to properly validate the system.
[K4] Conduct Supplier Assessment 
Since in our case URS [R1] is sent to 
several integrators/suppliers of supervi-
sory computer systems, it is necessary to 
carry out an assessment of suppliers before 
choosing the best one, in order to assess 
that the supplier is able to develop com-
puter systems, in accordance with the phar-
maceutical industry standards and company 
internal standards. The assessment shall be 
recorded in the Supplier Evaluation Report 
[R3] document. In case that we already 
conducted supplier assessment in the past 
(e.g. 5 years) and supplier obtained posi-
tive assessment results, the assessment im-
plementation is not necessary, when vali-
dating a new computer system/application. 
Nevertheless, we conduct the supplier as-
sessment once again, if the supplier has 
been gone through a major organizational 
change. 
[K5] Create Validation Plan (VP)
VP [R4] is a document describing the 
computer system validation method and 
principles for validating a computer sys-
tem. The basis for producing VPs are URS 
[R1] and HLRA [R2]. We also consider 
the Supplier Evaluation Report [R3]. VP 
describes, on the aggregate level, which 
activities are planned and should be con-
ducted for successfull system validation, 
which internal SOP and general procedures 
should be updated, which trainings should 
be conducted and who needs to be trained, 
which documents will be created during the 
validation process, who will draw them up, 
who will review them and who will approve 
the validation documentation.  
5.3.2. Specifying sub-process
When the new computer system basis is 
defined and HLRA and VP are developed, 
we begin to develop the computer sys-
tem functionality and specifications, based 
on the approved URS. The sub-process 
diagram – Specifying (Figure 3) shows de-
tails of the key steps for conducting these 
activities.
11
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Figure 3. Sub-process diagram – Specifying
A more detailed description of the 
specific steps within the sub-process 
Specifying is presented below.
[K6] Create Design Documents
URS [R1] is the basis for creating 
the Functional Specification (FS), the 
Software Design Specification (SDS) and 
the Hardware Design Specification (HDS). 
The documentation is created by the com-
puter system supplier, or, alternatively, pro-
duced by the company, when the computer 
system is internally developed. In our case, 
the monitoring/controlling system SCADA 
is developed by an external supplier, which 
creates the design documents and sends us 
the documents for review and approval.
In design documents, the suppliers de-
scribe how they see and understand the 
computer system, according to the given 
URS, while it is desirable to indicate the 
references to the URS ID, as shown in 
Table 2. Only in such a way, it can be en-
sured that the supplier will create a com-
puter system in accordance with the URS. 
Table 2 presents an example of system 
functionalities described in FS. 
Journal of Contemporary Management Issues
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Table 2. FS example – System functionalities in FS document




Screen display of the control system contains all the standard elements, 
displays and interfaces for the review and control of the production 
process with the entire technological procedure, showing all the necessary 




The display of the captured data in the form of a graph (histography) is part 
of the iFix application, which, in addition to other functionalities, enables 




When reviewing the FS, we note all 
disparities with the given URS and the 
whole process is formalized into Design 
Qualification (DQ). If no discrepancies are 
detected during the inspection, this should 
nevertheless be documented and formalized in 
the DQ.
[K7] Conduct Design Qualification 
(DQ)
In our SCADA system case, at this 
point we receive the design documenta-
tion from the supplier for review and ap-
proval (FS, SDS and HDS [R5]). Since 
it is in our interest to obtain such a com-
puter system, as defined in the URS [R1], 
at this stage, we need to review of whether 
the design documentation provided by the 
supplier actually covers all of our URS 
requirements. This is important, as the 
supplier will build the computer system 
exactly as it has been defined in FS, SDS 
and HDS. After completing the compari-
son between the URS and the FS, SDS and 
HDS, appointed responsible persons ap-
prove the record that was created, when 
review of the documents was conducted. 
It is formally called the design qualifica-
tion - DQ [R6]. In the event that deviations 
from the URS have been detected in the 
DQ, the supplier must update the design 
documentation to embrace all URSs, or 
the user may limit its requirements for the 
computer system and create new URS.
It is important to emphasize that, in the 
pharmaceutical industry, the functionality 
of a computer system can only restricted, 
if it does not have any impact on regulato-
ry requirements. However, we cannot limit 
the requirements, imposed indirectly by the 
regulatory authorities, in any way, since, in 
this case, we validate a computer system 
that does not comply with the prescribed 
regulations from the start.
[K8] Conduct (Functional) Risk 
Assessment (FRA)
After confirming FS, SDS and HDS 
[R5] and considering this documenta-
tion together with URS [R1], we produce 
the FRA [R7], in which we evaluate each 
of the URSs, according to GxP computer 
system individual functionality criticality. 
We evaluate the possible risks we could 
encounter, in the event of a failure or non-
performance of each functionality, assess 
the frequency at which these events can 
occur, the criticality of these events, in 
terms of impact on product quality, patient 
safety, safety at work, etc. and we evalu-
ate the possibility of detecting an improper 
13
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operation or error. Based on the results of 
each computer system functionality criti-
cality assessments, we decide what kind of 
testing will be selected for each function-
ality. The tests can be simple or complex, 
and each decision needs to be explained 
and commented on, in relation to each 
functionality, i.e. we need to explain why 
we have chosen a certain type of testing. 
Therefore, the evaluation and descrip-
tion of risks are implemented for the 
events where the computer system would 
not function in accordance with, in our 
case, the functionalities specified in FS. 
Where the risk of the system not operating 
as intended is high, the appropriate 
Installation Qualification (IQ), Operational 
Qualification (OQ) and Performance 
Qualification (PQ) testing of the computer 
system are performed at the verification 
phase.
An example of risk analysis is shown in 
Table 3, where GxP criticality of the system 
functionalities is evaluated (YES/NO), the 
impact of errors/deviations, the possibil-
ity of an error/deviation, and the possibil-
ity of not detecting an error/deviation are 
determined (H - high impact/possibility; M 
- mean impact/possibility; L - low impact/
possibility).
Table 3. FRA example
FS
 ID






















































































No process data for review; no 
possibility of process data review; 
regulatory inconsistency; GMP 
deviation investigation is not possible 
in full scale; product cannot be 
released on the market.
YES H L L / OQ test
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Figure 4. Sub-process diagram – Development/Building
A more detailed description of the 
specific steps within the sub-process of 
Development/building is presented below.
[K9] System/application development 
and documentation
At this stage, we start with the com-
puter system construction (in our case – the 
SCADA system). In development, the basic 
principles, defined in the VP [R4], must be 
taken into account, while the main docu-
mentation for development are FS, SDS and 
HDS [R5]. The result is a computer system 
that complies with the URS, and in our 
case, the supplier is also obliged to produce 
technical and user documentation [R9]. All 
users are required to study them closely be-
fore using the computer system.
5.3.4. Verification sub-process
As a part of the verification, we verify 
that the computer system works in accord-
ance with the users’ expectations. As shown 
in Figure 5, this is checked by IQ, OQ and 
PQ tests.
5.3.3. Development/Building sub-process
Figure 4 shows the inputs required for 
the construction of a computer system, as 
well as the result that follows - a developed 
computer system and the related technical 
and user documentation.
15
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Figure 5. Sub-process diagram - Verification
More detailed description of spe-
cific steps, within the sub-process of 
Verification, is presented below.
[K10] Test Planning (according to VP 
[R4])
When a computer system is developed 
(a SCADA system, in this case), it must 
pass robust testing to prove that it works 
faultlessly and in accordance with the 
Journal of Contemporary Management Issues
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specifications. Validating a computer sys-
tem scope and methodology is prescribed 
by the VP, and the Test plan [R10] fur-
ther describes which IQ, OQ and PQ tests 
are required. When we have a developed 
and approved tests plan, we write the IQ 
[R10.1], OQ [R10.2] and PQ [R10.3] test 
specifications, where we define what we 
test, how to perform the test, and what is 
the expected result.
[K11] Testing
We test the system, in accordance with 
the test plan [R10] on pre-approved test 
specifications IQ [R10.1], OQ [R10.2] and 
PQ [R10.3], which are based on the results 
from the FRA. Installation of a computer 
system is tested with: an IQ test, which is a 
documented verification that the computer 
system is installed in accordance with the 
pre-approved specifications (International 
Society for Pharmaceutical Engineering, 
ISPE, 2008, p. 209, International Society for 
Pharmaceutical Engineering - ISPE, 2014); 
OQ test, which is a documented verification 
of pre-approved specifications that computer 
system performs as intended throughout all 
anticipated operating ranges (International 
Society for Pharmaceutical Engineering, 
ISPE, 2008, p. 334, International Society 
for Pharmaceutical Engineering - ISPE, 
2014a) and PQ test, which is a documented 
verification that the system is capable of 
operating and/or controlling (in our case 
production) processes during operation in its 
specified production environment in accord-
ance with the pre-approved specifications 
(International Society for Pharmaceutical 
Engineering - ISPE, 2008, p. 284, 
International Society for Pharmaceutical 
Engineering - ISPE, 2014b). The results of 
completed test specifications, obtained after 
the tests, are called test reports. This gives 
three sets of IQ test reports [R11.1], OQ test 
reports [R11.2], and PQ test reports [R11.3]. 
In cases where an error occurred in the 
course of testing and the testing was not suc-
cessful or was only partially successful, this 
is documented as a test deviation. Both devi-
ations as well as the relevant test reports are 
summarized in the Test and Deviation Report 
[R11] document. 
If we look at the continuation of our 
case, it is clear from Table 4 that both func-
tionalities of a computer system need to be 
tested with the OQ test. The test specifica-
tion itself must be approved before the test-
ing starts, as the test steps after the approval 
of the test specification are carried out on 
a copy of the approved test specification. 
The expected result, appropriateness, date, 
and signature are recorded manually in the 
fields provided for that purpose during the 
test implementation. In Table 4 we present 
an example of the OQ test specification, 
with the manually entered text being greyed 
out in the table.
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Table 4. OQ test example
Test name: OQ-1_screen test Prerequisite: Approved FS and FRA













Run and login 
into application 
iFix. Verify if on 
the control screen 
whole production 
process is shown, 
together with 
process values, 
time and date and 
logged-in user.
The screen 













Test name: OQ-2_parameters and history test Prerequisite: Approved FS and FRA
1 URS-F-51 FS-HI-01
Open „history“ in 
iFix. Verify that 
the control system 
records all process 
parameters in the 
















Open »history« in 
iFix and verify that 
the graph shows 
time on X axis and 




on X axis and 
parameter 











If the test report [R11] indicates that the 
computer system deviations are recorded, 
we have to eliminate them. The method of 
removing the deviations depends on the er-
ror type. In these cases, it may also be nec-
essary to correct the design of the computer 
system itself. The deviation is successfully 
resolved when repeated tests are success-
fully completed without deviations.
[K13] Create Traceability Matrix 
(TM)
What we demanded from the computer 
system supplier is defined in the URS [R1] 
and what we actually obtained is in FS, 
SDS and HDS [R5]. We have also exam-
ined the possible deviations, by comparing 
FS, SDS, HDS and URS and documented 
them in the DQ [R6]. It is, also, necessary 
to provide traceability, where it is evident, 
in a transparent manner, whether all URS 
have been considered in the design docu-
ments (this is already checked in DQ) and 
which tests (IQ, OQ, PQ) were used to 
test these requirements. To start the crea-
tion of TM [R12], there is no need to wait 
for the computer system verification, as we 
can start to build it earlier (during the de-
sign qualification - DQ). This ensures the 
first part of the traceability between URS 
and FS, SDS and HDS. The second part is 
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provided by IQ, OQ and PQ tests, where we 
connect the design documentation with test 
reports. As already mentioned, each user’s 
request is marked with a unique identifier 
(ID), so that we can guarantee the traceabil-
ity of document designs and tests. If we find 
out that we have failed to test one of the 
computer system functionality, this must be 
documented and, retrospectively, we must 
perform testing.
Once the tests are completed, we can 
build the whole TM, to verify and ensure 
that all the required URS functionalities 
were duly considered by the supplier and 
tested, in accordance with the FRA results. 
TM for our example is shown in Table 5.
Table 5. TM example
URS FS SDS HDS IQ OQ PQ Comment
URS-F-49 FS-EP-01 / / / OQ-1_screen test – step 1 / Complies
URS-F-50 FS-EP-01 / / / OQ-1_screen test – step 1 / Complies
URS-F-51 FS-HI-01 / / / OQ-2_parameters and history test – steps 1, 2 / Complies
5.3.5. Report sub-process
Figure 6 shows last activities needed be-
fore the release of the computer system into 
production and operational use.
Figure 6. Sub-process diagram – Report
A more detailed description of the spe-
cific steps within the sub-process Report is 
presented below.
[K14] Conduct User Training
Before the system goes into produc-
tion and operational use, it is necessary to 
ensure that all (prospective) users of the 
computer system are trained, by using the 
Technical and User documentation [R9]. It 
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is also necessary to train users on instruc-
tions or company procedures that describe 
the process and workflow, controlled by the 
computer system. The training of users is 
documented in the Training report [R13].
[K15] Create Validation Report (VR)
When all the activities envisaged in the 
VP [R4] are properly completed, this is 
listed in VR [R14]. A validated VR means 
that the computer system (in our case - the 
SCADA system) is successfully validated 
and can be routinely operated without any 
restrictions. The last approval date on VR 
means the computer system validation date 
(CSV date).
6. DISCUSSION
The paper addresses two research ques-
tions. The first one is related to the standard 
operating procedures included in a specific 
pharmaceutical company QMS for comput-
er systems validation.
In accordance with this question, the 
paper identified standard operating pro-
cedures, representing the elements of the 
quality system for the validation of com-
puter systems in conformance with the re-
quirements of the European and US legisla-
tion, governing the pharmaceutical industry. 
Today, one of the major challenges in de-
signing a QMS in the field of computer 
systems are either wrong, or simplified in-
terpretations of regulatory requirements. 
Errors in content or non-conformance with 
regulatory requirements often occur, be-
cause of lack of understanding of computer 
usage and computer system definitions, 
and/or lack of understanding how computer 
systems work. Although the regulatory re-
quirements are basically general, the key 
to defining and designing a proper QMS 
is understanding and correct interpretation 
of regulatory requirements, combined with 
the knowledge and understanding the actual 
operation of computer systems. Finally, for 
a successful computer system validation, 
we also need to understand the actual work 
processes. The presented established QMS 
for the computer system validation is the 
result of the case of a specific legal require-
ments interpretation, related to a pharma-
ceutical company.
In accordance with the second research 
question on how to perform the computer 
system validation, considering the pharma-
ceutical industry regulatory requirements, 
we studied the basic validation process ele-
ments of a computer-aided system. To this 
end, we used the action research method in 
conjunction with the case study to test the 
usefulness of a general V-model and de-
termine sub-processes for all stages of the 
computer system validation process, con-
sidering the regulatory requirements. The 
paper defines the validation process for a 
computer system and presents and explains 
it on a practical example in the pharma-
ceutical industry. The study confirms that 
the V-model is an appropriate basis for the 
validation of computer systems in the phar-
maceutical industry and that the established 
QMS, consisting of the general and specific 
standard operating procedures, represents 
an appropriate framework for the imple-
mentation of computer system validation. 
The experience from this highly regulated 
industry, however, can be appropriately 
used in other, less regulated industries, to 
provide the basic purpose of validation, 
where ensuring data integrity is a key re-
quirement for operation of the computer 
systems.
The paper contributes to understanding 
of interpretation of regulatory requirements 
in the computer system validation field in 
Journal of Contemporary Management Issues
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the pharmaceutical industry. We do not vali-
date computer systems to successfully un-
dergo inspections, but rather to fully ensure 
the data integrity, to minimize quality risks 
of a computer system or IT applications and 
to improve the overall product quality. It is 
important for the pharmaceutical industry 
that all suppliers and integrators of comput-
er-aided systems, working with pharmaceu-
tical companies at the GxP level, be aware 
that the set of regulations, consequently, ap-
plies to them, as well. They must be able to 
demonstrate compliance with the regulatory 
requirements and, in addition, the regula-
tions and internal standards of the pharma-
ceutical company, with which they cooper-
ate. Pharmaceutical companies are obliged 
to carry out audits of the suppliers and in-
tegrators with whom they cooperate, and 
these assessments are becoming increasing-
ly rigorous in the computer systems field.
The presented structure of the QMS has 
been designed for a specific pharmaceutical 
company, operating in a highly regulated 
environment. The quality system elements 
shown also represent merely a framework 
for operational computer system valida-
tion. Therefore, future work should be fo-
cused on testing the appropriateness of the 
presented QMS structure within other phar-
maceutical companies. Similar limitation 
is related to the use of a single case study 
for identification of process validation ele-
ments. Using a single case study enables the 
exploration of a particular field, problem, or 
situation in depth and in relation to a spe-
cific context, in our case, as determined by 
the regulatory framework. In order to verify 
the presented validation process, it is neces-
sary to add additional case studies, within 
the same context, i.e. the pharmaceutical 
industry. In addition, the appropriateness 
of presented QMS structure and valida-
tion process, or respectively, the need for 
their adaptation and/or simplification, in 
another context, e.g. less regulated indus-
tries, should also be investigated.
7. CONCLUSION
This paper identifies elements of com-
puter systems validation QMS and process, 
for a specific case of a pharmaceutical or-
ganization. In the pharmaceutical industry, 
the computer system should be validated 
in accordance with the regulatory require-
ments. Based on the European and US le-
gal requirements, we defined general and 
specific standard operating procedures, 
which represent QMS elements for com-
puter system validation in a pharmaceutical 
organization. The use of the QMS, which 
meets the strict pharmaceutical industry 
legal requirements, is not limited to it, but 
its elements are also applicable to other in-
dustries. The presented QMS can provide 
guidelines for all companies that need to 
develop an appropriate framework for com-
puter systems validation and implementa-
tion of effective management of computer 
system validation processes.
With the production computer system 
validation process example in the pharma-
ceutical industry, we assure a more pro-
found understanding of computer system 
validation implementation in practice, with 
the emphasis on meeting pharmaceutical in-
dustry regulatory requirements. As a basic 
premise, we use the V-model methodology 
to approach the validation. Planning, speci-
fication, development/building, verification 
and reporting, as the key five activities of 
the project/validation of a computer system, 
are presented, by using process diagrams, 
based on a practical validation example of 
a SCADA manufacturing computer-aided 
system. 
21
Management, Vol. 25, 2020, No. 2, pp. 1-23
B. Rusjan: COMPUTER SYSTEM VALIDATION: EXAMPLE OF QUALITY MANAGEMENT ...
References
1. Eisenhardt, K.M. (1989). Building
Theories from Case Study Research.
The Academy of Management Review,
14 (4), 532-550.
2. European Commission. (2011a).
EudraLex – Volume 4 Good
Manufacturing Practice Medicinal
Products for Human and Veterinary Use,
Chapter 4: Documentation, available at:
http://ec.europa.eu/health/files/eudralex/
vol-4/chapter4_01-2011_en.pdf (ac-
cessed 25 February 2017).
3. European Commission. (2011b).
EudraLex – Volume 4 Good
Manufacturing Practice Medicinal
Products for Human and Veterinary Use,
Annex 11: Computer Systems, available
at: http://ec.europa.eu/health/files/eu-
dralex/vol-4/annex11_01-2011_en.pdf
(accessed 25 February 2017).
4. European Commission. (2013a).
EudraLex – Volume 4 Good manu-




5. European Commission (2013b). EU




6. European Compliance Academy
(2011a). Introduction & Welcome. ECA 
Education Course – Computer Validation
The GAMP5 Approach. Vienna, Austria:
Concept Heidelberg GmbH.
7. European Compliance Academy (2011b).
Laws, Regulations and Guidelines for
Computer and Control Systems. ECA 
Education Course – Computer Validation
The GAMP5 Approach. Vienna, Austria:
Concept Heidelberg GmbH.
8. European Compliance Academy (2011c).
The GAMP5 Approach to Computer
Systems Validation. ECA Education
Course – Computer Validation The
GAMP5 Approach. Vienna, Austria:
Concept Heidelberg GmbH.
9. Gill, A.Q, Chew, E. (2019).
Configuration information system ar-
chitecture: Insights from applied ac-
tion design research. Information &
Management, 56 (4), 507-525.
10. Huber, L. (2012). Computer System
Validation – Tutorial, available at:
http://www.labcompliance.com/tutori-
al/csv/ (accessed 18 January 2014).
11. International Society for 
Pharmaceutical Engineering - ISPE.
(2008). GAMP 5: A Risk-based
Approach to Compliant Gxp Computer
Systems. Tampa, Florida: International
Society for Pharmaceutical
Engineering.
12. International Society for Pharmaceutical
Engineering - ISPE. (2014a). ISPE




(accessed 26 April 2014).
13. International Society for Pharmaceutical
Engineering - ISPE. (2014b). ISPE




(accessed 26 April 2014).
14. Koshy, E., Koshy, V. and Waterman, H.
(2011), Action research in Healthcare,
1st ed., Sage Publications Ltd., London.
15. Lopez, O. (2012). For Life Science
Professionals, Annex 11 and 21 CFR
Part 11: Comparisons for International
Compliance, available at: http://
www.mastercontrol.com/newsletter/
Journal of Contemporary Management Issues
22
annex-11-21-cfr-part-11-comparison.
html (accessed 25 February 2017).
16. McDowall, R. D. (2010). Understanding
and interpreting the GAMP5 life cy-
cle models for software. Spectroscopy, 
25(4), 22–31.
17. MetricStream (2014). Systems 
Validation for 21CFR Part 11 
Compliance, available at:  http://www.
metricstream.com/insights/sys_valida-
tion.htm (accessed 25 February 2017).
18. PIC/S (2007). Pharmaceutical Inspection
Co-Operation Scheme Guidance – Good 
Practices For Computerised Systems In 
Regulated Gxp Environments, available 
at: http://www.picscheme.org/pdf/27_pi-
011-3-recommendation-on-computer-
ised-systems.pdf (accessed 23 December 
2013).
19. Ranbaxy Laboratories Limited (2014).
Data Integrity, available at: http://www.
slideshare.net/skvemula/presentation-
on-data-integrity-in-pharmaceutical-in-
dustry# (accessed 21 May 2014).
20. Sallubier, T., Rusjan, B. (2017).
Oblikovanje sistema kakovosti za vali-
dacijo računalniških sistemov – primer 
farmacevtske industrije, Revija za uni-
verzalno odličnost, 6 (3), 274-291. 
21. Sai, D.C., Bhavyasri, K., Rambabu,
D. (2019). Role of Computer System 
Validation to Safeguard Data Integrity 
in Pharmaceutical Industry-A 
Review, International Journal of 
Pharmaceutical Science Invention, 8 
(1), 35-41.
22. Saunders, M., Lewis, P. and Thornhill,
A. (2009), Research Methods for 
Business Student, 5th ed., Pearson 
Education Limited, Harlow. 
23. Siggelkow, N. (2007). Persuasion with
case studies, Academy of Management 
Journal, 50 (1), 20-24. 
24. Singh A.,  Singour, P., Singh, P. (2018).
Computer system validation in the per-
spective of the pharmaceutical indus-
try. Journal of Drug Delivery and
Therapeutics, 8 (6), 359-365.
25. Tedstone, B. (2012). Computer
Systems Validation. Computer Systems
Validation and Quality Assurance
blog, available at: http://computersys-
temsvalidation.blogspot.com/2012/11/
GAMP-Software-Category.html (ac-
cessed 27 April 2014).
26. U.S. Food and Drug Administration
- FDA (2002). General Principles
of SoftwareValidation; Final
Guidance for Industry and FDA 
Staff. U.S. Department Of Health
and Human Services Food and Drug
Administration, available at:
27. ht tp : / /www.fda .gov /downloads /
MedicalDevices/Device Regulationand
Guidance /Gu idanceDocumen t s /
ucm085371.pdf (accessed 25 February
2017).
28. U.S. Food and Drug Administration
- FDA (2003). Guidance for Industry 
Part 11, Electronic Records; Electronic 
signatures – Scope and Application. 
U.S. Department of Health and Human 




29. U.S. Food and Drug Administration –
FDA (2004). Pharmaceutical cGMP‘s 
for The 21St Century, A Risk Based 
Approach, Final Report. U.S. Department 
Of Health and Human Services Food 








Management, Vol. 25, 2020, No. 2, pp. 1-23
B. Rusjan: COMPUTER SYSTEM VALIDATION: EXAMPLE OF QUALITY MANAGEMENT ...
30. U.S. Food and Drug Administration -
FDA (2006). Guidance for Industry,
Quality Systems Approach to
Pharmaceutical CGMP Regulations,
available at: http://www.fda.gov/
downloads/Drugs/ . . . /Guidances /
UCM070337.pdf (accessed 25 
February 2017).
31. U.S. Food and Drug Administration -
FDA (2013a). CFR – Code of Federal
Regulations Title 21, Volume 4 – Part
211 Current Good Manufacturing
Practice for Finished Pharmaceuticals,
available at: http://www.accessdata.
fda.gov/scripts/cdrh/cfdocs/cfcfr/cfr-
search.cfm?cfrpart=211  (accessed 26
December 2013).
32. U.S. Food and Drug Administration –
FDA (2013b). CFR – Code of Federal
Regulations Title 21, Volume 4 – Part
11 Electronic Records; Electronic
Signatures, available at:  http://www.
accessdata.fda.gov/scripts/cdrh/cfdocs/
cfcfr/cfrsearch.cfm?cfrpart=11 (ac-
cessed 26 December 2013).
33. Velkovrh Remec, B. (2007). Validation




34. Yin, R.K. (2009), Case study research:
Design and methods, 4th ed., Sage,
Thousand Oaks.
VALIDACIJA RAČUNALNOG SUSTAVA: PRIMJER 
UPRAVLJANJA DIZAJNA SUSTAVA UPRAVLJANJA 
KVALITETOM I PROCESNE IMPLEMENTACIJE
Sažetak
Cilj ovog rada je prezentacija sustava upravljanja kvalitetom (Quality Management System - QMS) 
za validaciju računalnih sustava te prikaz validacijskog procesa na praktičnom slučaju farmaceutske 
tvrtke. Na temelju europskih i američkih pravnih zahtjeva, definiramo QMS za validaciju elemenata 
računalnog sustava. Primjer procesa validacije, zasnovan na korištenju općeg V-modela, pruža detalj-
no razumijevanje praktične implementacije validacije u praksi. Validacija računalnog sustava u kon-
kretnoj organizaciji može se temeljiti na općim i specifičnim standardnim operativnim procedurama, 
koje formiraju QMS. Validacijske aktivnosti planiranja, specificiranja, razvoja/izgradnje, verificiranja 
i izvještavanja se prezentiraju korištenjem procesnih dijagrama, zasnovanih na praktičnom primjeru 
validacije računalnog sustava za upravljanje proizvodnjom Supervisory Control and Data Acquisition 
(SCADA). Empirijski dio rada koristi dvije istraživačke strategije: studiju slučaja i akcijsko istraživa-
nje. Predstavljeni procesa validacije, kao i primjer računalnog sustava za upravljanje kvalitetom mogu 
pružiti smjernice za sva poduzeća, kojima su računalni sustavi značajni. Iako se prezentirani QMS i 
proces validacije računalnog sustava zasnivaju na primjeru konkretnog farmaceutskog poduzeća i nje-
govih pravnih zahtjeva, iskustva iz visoko regulirane industrije se mogu na odgovarajući način koristiti 
i u manje reguliranim industrijama. Za verifikaciju predloženog modela, potrebno ih je dalje testirati, 
kako u farmaceutskim, tako i u drugim, manje reguliranim industrijama.
Ključne riječi: sustav za upravljanje kvalitetom, računalni sustavi, validacija, V-model, farmace-
utska industrija
